Vivos Therapeutics (VVOS) FCF Margin (2020 - 2026)
Vivos Therapeutics' (VVOS) quarterly FCF Margin came in at 117.06% in Q1 2026, up 1298.0% year-on-year from 8.37% in Q1 2025, and up 44.99% on a QoQ basis from 212.81% in Q4 2025.
Vivos Therapeutics (VVOS) FCF Margin (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has 7 years of FCF Margin data on file, last reported at 117.06% in Q1 2026.
- On a quarterly basis, FCF Margin rose 1298.0% year-over-year to 117.06% in Q1 2026; TTM through Mar 2026 was 115.21%, a 1593.0% decrease from a year earlier, with the FY2025 full-year figure at 117.23%, down 2896.0% from the prior year.
- FCF Margin for Q1 2026 stood at 117.06%, up from 212.81% in the prior quarter.
- Over the last five years, FCF Margin for VVOS reached as high as 60.7% in Q3 2025 and fell as low as 212.81% in Q4 2025.
- Historically, FCF Margin has averaged 109.87% across 5 years, with a median of 106.37% in 2023.
- Across the five-year window, FCF Margin soared 7715 bps in 2023 and plunged 12861 bps in 2025, its largest moves.
- Year by year, FCF Margin stood at 81.34% in 2022, then slumped by 31 bps to 106.37% in 2023, then gained by 21 bps to 84.21% in 2024, then slumped by 153 bps to 212.81% in 2025, then jumped by 45 bps to 117.06% in 2026.
- Per Business Quant data, the three most recent FCF Margin figures were 117.06% in Q1 2026, 212.81% in Q4 2025, and 60.7% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.88 Bn | 176.59 Bn | 6.27 Bn | 8.20% |
| 2 | Stryker | 128.94 Bn | 126.06 Bn | 3.81 Bn | 6.89% |
| 3 | Medtronic | 108.75 Bn | 99.53 Bn | 6.41 Bn | 21.26% |
| 4 | Boston Scientific | 68.65 Bn | 67.19 Bn | 3.61 Bn | 3.29% |
| 5 | Edwards Lifesciences | 48.22 Bn | 44.55 Bn | 1.29 Bn | -1.28% |
| 6 | Dexcom | 28.43 Bn | 27.31 Bn | 750.30 Mn | 37.67% |
| 7 | GE HealthCare Technologies | 28.32 Bn | 26.03 Bn | 1.98 Bn | 2.18% |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.10 Bn | 21.98 Bn | 2.07 Bn | 6.68% |
| 10 | Vivos Therapeutics | 5.71 Mn | 3.60 Mn | 3.06 Mn | -117.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -117.06% |
| Dec 31, 2025 | -212.81% |
| Sep 30, 2025 | -60.70% |
| Jun 30, 2025 | -111.81% |
| Mar 31, 2025 | -130.04% |
| Dec 31, 2024 | -84.21% |
| Sep 30, 2024 | -112.51% |
| Jun 30, 2024 | -77.55% |
| Mar 31, 2024 | -78.01% |
| Dec 31, 2023 | -106.37% |
| Sep 30, 2023 | -71.68% |
| Jun 30, 2023 | -97.00% |
| Mar 31, 2023 | -93.05% |
| Dec 31, 2022 | -81.34% |
| Sep 30, 2022 | -139.94% |
| Jun 30, 2022 | -123.49% |
| Mar 31, 2022 | -170.20% |
| Dec 31, 2021 | -102.50% |
| Sep 30, 2021 | -97.98% |
| Jun 30, 2021 | -112.30% |